Q-omics provides the consensus-scored IL25 profile across patient tissues and cancer cell-line models. IL25 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL25 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, IL25 RNA expression shows 7,480 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight HNSC, THCA, and ESCA as cancer lineages where IL25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL25 survival associations across molecular data types. IL25 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL25 RNA expression–survival associations across cancer types. High IL25 expression shows unfavorable associations in KICH and KIRC, but favorable associations in HNSC, CESC, UCS and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify HNSC as the clearest survival context for IL25 RNA expression.
This table summarizes IL25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for IL25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL25 shows lower tumor expression in THCA, KICH, BLCA and PRAD and higher tumor expression in HNSC and LUSC. The THCA box plot shows higher IL25 RNA expression in normal versus tumor tissue (log2 FC = −0.122, t-test p < 0.001).
This table shows molecular features associated with IL25 in patient tissues and cancer cell lines. In patient samples, IL25 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IL25 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SKIN.
